HENG TAI(00197)
Search documents
亨泰(00197) - 提名委员会职权范围
2025-09-26 10:17
提名委員會 - 職權範圍 於 2005 年 7 月 1 日採納 並於 2008 年 6 月 30 日、2012 年 2 月 28 日、2015 年 8 月 11 日,2018 年 12 月 31 日及 2025 年 9 月 26 日修訂 1 成立 亨泰消費品集團有限公司(「本公司」) (於開曼群島註冊成立之有限責任公司) 3 出席會議 4 舉行會議次數及程序 1 本公司董事會(「董事會」)於 2005 年 7 月 1 日決議組成並成立提名委員會(「提名委員 會」),其職權及具體職務載述如下。 2 成員 2.1 提名委員會成員由董事會選任,人數不得少於三名,大部分成員須為獨立非執行董事。董 事會為提名委員會委任至少一名不同性別的董事。 2.2 提名委員會主席須由董事會委任且必須由董事會主席或一名獨立非執行董事擔任。倘提名 委員會主席及/或獲委任的副主席缺席,則其餘出席會議的成員須選出其中一名成員主持 會議。倘該會議將處理有關主席續任的事宜,則董事會主席不得主持委員會。 3.1 只有提名委員會成員方有權出席並於提名委員會會議投票表決。但應提名委員會之邀請, 其他董事會成員、高級管理人員、外聘顧問或其他視為合適之人 ...
智通港股52周新高、新低统计|9月19日





智通财经网· 2025-09-19 08:43
Group 1 - As of September 19, 93 stocks reached their 52-week highs, with Huake Intelligent Investment (01140), Xincheng Power (01148), and Huashang Energy (00206) leading the increase rates at 22.30%, 20.00%, and 17.65% respectively [1] - The closing prices for the top three stocks that reached new highs are Huake Intelligent Investment at 0.170, Xincheng Power at 0.300, and Huashang Energy at 0.305 [1] - Other notable stocks that reached new highs include Handa Fu Holdings (01348) with a high rate of 16.89% and Meijiehui Holdings (01389) at 13.75% [1] Group 2 - The report also lists stocks that reached their 52-week lows, with Shanga Holdings (00412) experiencing the largest decline at -34.98%, followed by Huaying Construction (01582) at -21.47% [3] - The closing price for Shanga Holdings is 3.360, while Huaying Construction closed at 0.360 [3] - Other stocks with significant declines include China Information Technology Equity (08568) at -17.74% and Tai Hing Properties (00277) at -11.90% [3]
亨泰(00197) - 董事会召开日期
2025-09-16 09:18
香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責,對 其準確性或完整性亦不發表任何聲明,並明確表示概不會就因本公告全部或任何部分 內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 HENG TAI CONSUMABLES GROUP LIMITED 亨泰消費品集團有限公司 ( 於開曼群島註冊成立的有限公司 ) (股份代號: 00197) 董事會召開日期 於本公告日期,董事會包括四名執行董事,分別為林國興先生(主席)、李彩蓮女 士、高勤建女士及陳卓宇先生;及三名獨立非執行董事,分別為麥潤珠女士、潘耀祥 先生及孔慶文先生。 香港,二零二五年九月十六日 亨泰消費品集團有限公司(「本公司」)董事會(「董事會」)宣布董事會將於二零二五年 九月二十六日(星期五)舉行會議,藉以(其中包括)批准刊發本公司及其附屬公司 截至二零二五年六月三十日止年度的經審核綜合年度業績公告及考慮宣派期末股息(如 有)。 代表董事會 亨泰消費品集團有限公司 主席 林國興 ...
亨泰拟开拓亚洲及欧洲出口市场 应对本土进口业务挑战
Zhi Tong Cai Jing· 2025-08-29 10:37
Core Viewpoint - The company aims to diversify its product offerings by exporting various new products from China to Asian and European markets, responding to the challenges faced in its current fast-moving consumer goods (FMCG) trade business [1][2] Group 1: Business Strategy - The company intends to expand its packaging food, beverage, and household consumer goods trade business due to significant improvements in the quality and price advantages of Chinese products [1] - The company is continuously reviewing its import trade operations to streamline unprofitable segments and reduce operational costs in response to increasing competition from local brands [1] - The company plans to expand its agricultural processing center in Dongguan, which serves as a crucial hub for fresh agricultural product trade, providing pre-prepared and cooked fresh produce to well-known fast-food chains and school canteens [1] Group 2: Market Conditions - The FMCG trade business is facing adverse market conditions due to the growing preference of Chinese consumers for local products, driven by competitive pricing and increased market share through advertising [1] - The company believes that its established supply chain and market expertise in China will support the development of its export business and local fresh agricultural product trade [2]
亨泰(00197.HK)有意拓展不同种类的新产品选项
Ge Long Hui· 2025-08-29 09:55
Core Insights - The company intends to expand its product offerings by exporting various new products from China to Asian and European markets to enhance its current trade in packaged foods, beverages, and fast-moving consumer goods [1] - The decision is driven by significant improvements in the quality of Chinese products and their price advantages, alongside increasing competition negatively impacting the company's existing import trade operations [1] - The company plans to streamline its unprofitable import trade operations while closely monitoring market conditions to maintain competitiveness in the fast-moving consumer goods sector [1] Business Expansion Plans - The company aims to expand its agricultural processing center located in Dongguan, China, which serves as a crucial hub for fresh agricultural product trade [1] - The processing center has seen stable growth in demand and revenue post-pandemic, providing pre-prepared, processed, and ready-to-cook fresh agricultural products to well-known fast-food chains and school canteens [1] - The company will explore further expansion of this business within the domestic market in China [1] Strategic Rationale - The board believes that entering new markets will help diversify the company's revenue sources and address the challenges faced by its fast-moving consumer goods trade [2] - The company is confident that its established supply chain and market expertise in China will support the development of its export business and local fresh agricultural product trade [2]
亨泰(00197) - 自愿公告 – 业务更新
2025-08-29 09:25
(股份代號: 00197) 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責,對 其準確性或完整性亦不發表任何聲明,並明確表示概不會就因本公告全部或任何部分 內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 HENG TAI CONSUMABLES GROUP LIMITED 亨泰消費品集團有限公司 ( 於開曼群島註冊成立的有限公司 ) 代表董事會 亨泰消費品集團有限公司 主席 林國興 自願公告 – 業務更新 本公告由亨泰消費品集團有限公司(「本公司」,連同其附屬公司,統稱「本 集團」)自願作出,旨在向本公司股東(「股東」)及潛在投資者更新本集團 的最新業務發展。 本公司董事(「董事」)會(「董事會」)謹此通知本公司股東及潛在投資 者,本集團有意拓展不同種類的新產品選項,由中國出口至亞洲及歐洲市場, 以擴充其現時的包裝食品、飲料及家庭消費品貿易業務(「快速消費品貿易業 務」)。此舉措的考量是因中國產品品質的大幅提升及其價格優勢,加上市場 競爭日益激烈而對本集團現有的進口貿易業務產生的不利影響。由於本地品牌 價格具有競爭力及透過廣告活動增加市場份額,使中國消費者對本地商品的偏 好日 ...
昊海生物科技与亨泰光学终止OK镜独家合作 获8000万元补偿并全资控股亨泰视觉
Zhi Tong Cai Jing· 2025-08-20 13:40
Core Viewpoint - The announcement details a significant partnership and investment involving昊海生物科技,亨泰光学, and亨泰视觉, which includes exclusive distribution rights and equity acquisition, indicating a strategic move to enhance market presence in the optical lens sector [1][2]. Group 1: Exclusive Distribution Agreement -昊海生物科技's subsidiary,昊海控股, has signed an exclusive distribution agreement with亨泰光学 and亨泰视觉 for high-end orthokeratology contact lenses "迈儿康myOK" in mainland China for a duration of 10 years, expiring on December 31, 2030 [1]. - The agreement also grants昊海控股 exclusive distribution rights for children's myopia management optical lenses "贝视得" in mainland China [1]. Group 2: Equity Acquisition -昊海发展, another subsidiary of昊海生物科技, has entered into an investment agreement to acquire a 55% stake in亨泰视觉 for RMB 25 million, making亨泰视觉 a controlled subsidiary and included in the consolidated financial statements of the company [1]. - Following a change in control of亨泰光学 due to a proposed acquisition by Carl Zeiss Vision International GmbH,昊海控股 and亨泰光学's major shareholders have signed a termination agreement for the existing cooperation [2]. - As part of the termination agreement,亨泰光学's major shareholders will pay昊海控股 a termination compensation of RMB 80 million [2].
昊海生物科技(06826)与亨泰光学终止OK镜独家合作 获8000万元补偿并全资控股亨泰视觉
智通财经网· 2025-08-20 13:30
Core Viewpoint - The company has entered into exclusive distribution agreements and investment agreements with Hengtai Optical and Hengtai Vision, which will significantly impact its market position in the high-end contact lens sector in China [1][2]. Group 1: Exclusive Distribution Agreements - The company’s wholly-owned subsidiary, Haohai Biotechnology Holdings, signed an exclusive distribution agreement with Hengtai Optical and Hengtai Vision for the high-end orthokeratology contact lens product "myOK" in mainland China for a duration of 10 years, expiring on December 31, 2030 [1]. - The agreement also includes the exclusive distribution rights for Hengtai Vision's optical lenses for children's myopia management, named "Beishide," in mainland China [1]. Group 2: Investment Agreement - The company’s subsidiary, Haohai Pharmaceutical Technology Development, has signed an investment agreement to acquire a 55% stake in Hengtai Vision for RMB 25 million, making Hengtai Vision a subsidiary and consolidating it into the company's financial statements [1]. Group 3: Termination of Existing Cooperation - Due to Carl Zeiss Vision International's intention to acquire 100% of Hengtai Optical, the existing cooperation between Haohai Holdings and Hengtai Optical will be terminated, with a compensation payment of RMB 80 million to Haohai Holdings [2]. - Following the termination, Hengtai Vision will transfer 45% of its shares from its minority shareholder to Haohai Development, making Hengtai Vision a wholly-owned subsidiary of Haohai Development [2].
Zhongshen Hengtai Capital Limited中深亨泰资本有限公司增持宏基集团控股2304万股 每股作价0.215港元

Zhi Tong Cai Jing· 2025-08-18 13:01
Group 1 - Zhongshen Hengtai Capital Limited increased its stake in Hongji Group Holdings (stock code: 01718) by acquiring 23.04 million shares at a price of HKD 0.215 per share, totaling HKD 4.9536 million [1] - After the transaction, Zhongshen Hengtai Capital Limited holds a total of 23.04 million shares, representing a 10% ownership stake in Hongji Group Holdings [1] - The transaction also involves other related parties, including Zhongshen Jianye Holding Limited, Zhongshen Xihe Enterprise Limited, and Sang Xianfeng [1] Group 2 - The acquisition was disclosed on August 15, 2024, and is part of a broader strategy by the involved parties to increase their holdings in Hongji Group Holdings [2] - The average price per share for the transaction was HKD 0.215, consistent across all related parties involved in the acquisition [2]
Zhongshen Hengtai Capital Limited中深亨泰资本有限公司增持宏基集团控股(01718)2304万股 每股作价0.215港元

智通财经网· 2025-08-18 12:58
Group 1 - Zhongshen Hengtai Capital Limited increased its stake in Hongji Group Holdings (01718) by acquiring 23.04 million shares at a price of HKD 0.215 per share, totaling HKD 4.9536 million [1] - After the transaction, Zhongshen Hengtai Capital Limited's total shareholding reached 23.04 million shares, representing a 10% ownership stake in Hongji Group Holdings [1] - The transaction involved other related parties, including Zhongshen Jianye Holding Limited, Zhongshen Xihe Enterprise Limited, and Sang Xianfeng [1]